相关实验视频

Updated: Jan 18, 2026

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

一种与发育性和性脑病变相关的新型KCNA2变异的功能性表征和体外药理学救援

Changning Xie¹, Miriam Kessi¹, Fang He¹

¹Department of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008 Hunan, China.

|September 12, 2025

概括

一种新的KCNA2突变 (p.S392F) 通过改变KV1.2通道功能,导致发育性和性脑病变. 这种混合的功能增益和功能丧失变体显示了对4-阿米诺皮里丁 (4-AP) 的潜在治疗反应.

科学领域:

神经科学是一个神经科学.
遗传学遗传学是一种遗传学.
分子生物学分子生物学

背景情况:

编码KV1.2通道的KCNA2突变与发育性和性脑病变 (DEE) 有关.
由KCNA2突变引起的DEE背后的精确机制在很大程度上是未知的.

研究的目的:

确定和描述与DEE相关的新型KCNA2突变 (p.S392F).
阐明p.S392F突变对Kv1.2通道活动和神经元功能的功能后果.
为了研究4-aminopyridine (4-AP) 的治疗潜力,以减轻p.S392F突变的影响.

主要方法:

在两个与DEE无关的患者中发现了一种新的KCNA2突变 (c.1175C>T,p.S392F).
利用西式涂抹,免疫细胞化学,细胞死亡试验和补丁电生理学来评估功能后果.
在细胞模型和初级神经元中评估了p.S392F突变对4-aminopyridine (4-AP) 的敏感性.
分析了来自KCNA2变种混合功能增益 (GOF) 和功能丧失 (LOF) 患者的临床数据.

主要成果:

这种p.S392F突变导致Kv1.2通道失活的超极化转移,表明GOF/LOF混合变体.
这种突变导致了细胞死亡的增加和神经元发射的减少,这部分是由4-AP救援的.
对11名患者的临床分析显示,,发育迟缓/智力障碍和言语迟缓的发病率为100%,其中36.36%的患者患有.
三名患有混合GOF/LOF变异的患者在接受4-AP治疗时出现了部分改善.

结论:

通过混合GOF/LOF通道活动确定了一种新的复发性KCNA2 p.S392F突变,导致DEE.
为混合GOF/LOF KCNA2变种建立了独特的基因型-表型关联,包括高率和发育问题.
突出了4-aminopyridine (4-AP) 对具有特定KCNA2突变的DEE患者的治疗潜力.

关键词:

4 - 氨基胺-4-氨基胺-4-氨基胺-4-氨基胺过敏症过敏症过敏症过敏症是一种病.功能获取 - 功能获取智力障碍智力障碍是一种智力障碍.在KCNA2中,KCNA2是KCNA2.

更多相关视频

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Identification and Classification of Position-specific GABA_A Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Published on: December 9, 2022

相关概念视频

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Voltage-gated Ion Channels

Voltage-gated Ion Channels

Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...